A subsidiary of Footstar has entered into an agreement to acquire New Hampshire specialty pharma company CPEX, which is developing Nasulin intranasal insulin spray. Nasulin is in Phase 2 development, and CPEX has been seeking to license the product or to sell the program outright. Read the company’s press release.
